Gilead’s Trodelvy Strategy Helped By Phase II Bladder Cancer Data

Gilead Sciences, Inc. unveiled new and updated positive data from a Phase II trial of Trodelvy (sacituzumab govitecan-hziy) in metastatic urothelial cancer (mUC) on 17 February, part of a dataset the company hopes will expand the antibody-drug conjugate into second-line treatment of bladder cancer.

The updated readout from Phase II TROPHY-U-01 arrived just two weeks after the Foster City, CA-headquartered company announced on 3 February that Trodelvy obtained US Food and Drug Administration approval...